A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

Stephen G. Chun, Randall Hughes, Baran D. Sumer, Larry L. Myers, John M. Truelson, Saad A. Khan, Tsung Wei Ma, Yang Xie, John S. Yordy, Susan Cooley, Jean Wu, Hak Choy, Lucien A. Nedzi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalCancer Investigation
DOIs
StateAccepted/In press - Nov 28 2016

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Radiotherapy
Confidence Intervals
Radiation
Disease-Free Survival
Maximum Tolerated Dose
Cisplatin
Neck
Head
Survival
TP protocol
130-nm albumin-bound paclitaxel
Cetuximab
Neoplasms

Keywords

  • Abraxane
  • cisplatin
  • erbitux
  • head and neck cancer
  • radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{02adf852252d4522956b4afd9c5a14d3,
title = "A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck",
abstract = "Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60{\%} (95{\%} confidence interval (CI) 0.42, 0.78), local control 71{\%} (95{\%} CI 0.55, 0.87), and overall survival 68{\%} (95{\%} CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.",
keywords = "Abraxane, cisplatin, erbitux, head and neck cancer, radiation therapy",
author = "Chun, {Stephen G.} and Randall Hughes and Sumer, {Baran D.} and Myers, {Larry L.} and Truelson, {John M.} and Khan, {Saad A.} and Ma, {Tsung Wei} and Yang Xie and Yordy, {John S.} and Susan Cooley and Jean Wu and Hak Choy and Nedzi, {Lucien A.}",
year = "2016",
month = "11",
day = "28",
doi = "10.1080/07357907.2016.1213275",
language = "English (US)",
pages = "1--9",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

AU - Chun, Stephen G.

AU - Hughes, Randall

AU - Sumer, Baran D.

AU - Myers, Larry L.

AU - Truelson, John M.

AU - Khan, Saad A.

AU - Ma, Tsung Wei

AU - Xie, Yang

AU - Yordy, John S.

AU - Cooley, Susan

AU - Wu, Jean

AU - Choy, Hak

AU - Nedzi, Lucien A.

PY - 2016/11/28

Y1 - 2016/11/28

N2 - Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.

AB - Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.

KW - Abraxane

KW - cisplatin

KW - erbitux

KW - head and neck cancer

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84997796774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997796774&partnerID=8YFLogxK

U2 - 10.1080/07357907.2016.1213275

DO - 10.1080/07357907.2016.1213275

M3 - Article

C2 - 27892728

AN - SCOPUS:84997796774

SP - 1

EP - 9

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

ER -